GPT and Hand-foot syndrome: During the follow-up period, 33 patients had at least one treatment-related AEs, and the most common AE during regorafenib treatment were elevated aspartate aminotransferase [17/41 patients (41.5%)], elevated alanine aminotransferase [16/41 patients (39%)] and hand-foot syndrome [14/41 patients (34.1%)] (Table 3).